
<document id="DBMI.pac171" origId="pac171">
	<sentence id="DBMI.pac171.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nIrbesartan\n\nAngiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II)."/>
	<sentence id="DBMI.pac171.s1" origId="s1" text="Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth."/>
	<sentence id="DBMI.pac171.s2" origId="s2" text="Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor."/>
	<sentence id="DBMI.pac171.s3" origId="s3" text="There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis."/>
	<sentence id="DBMI.pac171.s4" origId="s4" text="Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity."/>
	<sentence id="DBMI.pac171.s5" origId="s5" text="Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure."/>
	<sentence id="DBMI.pac171.s6" origId="s6" text="Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis."/>
	<sentence id="DBMI.pac171.s7" origId="s7" text="Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known."/>
	<sentence id="DBMI.pac171.s8" origId="s8" text="Hydrochlorothiazide\n\nHydrochlorothiazide is a thiazide diuretic."/>
	<sentence id="DBMI.pac171.s9" origId="s9" text="Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts."/>
	<sentence id="DBMI.pac171.s10" origId="s10" text="Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium."/>
	<sentence id="DBMI.pac171.s11" origId="s11" text="The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics."/>
	<sentence id="DBMI.pac171.s12" origId="s12" text="The mechanism of the antihypertensive effect of thiazides is not fully understood."/>
	<sentence id="DBMI.pac171.s13" origId="s13" text="12.2 Pharmacodynamics\n\nIrbesartan\n\nIn healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions."/>
	<sentence id="DBMI.pac171.s14" origId="s14" text="Inhibition was complete (100%) 4 hours following oral doses of 150 mg or 300 mg and partial inhibition was sustained for 24 hours (60% and 40% at 300 mg and 150 mg, respectively)."/>
	<sentence id="DBMI.pac171.s15" origId="s15" text="In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels."/>
	<sentence id="DBMI.pac171.s16" origId="s16" text="Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses."/>
	<sentence id="DBMI.pac171.s17" origId="s17" text="In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction."/>
	<sentence id="DBMI.pac171.s18" origId="s18" text="In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations."/>
	<sentence id="DBMI.pac171.s19" origId="s19" text="There was no effect on serum uric acid during chronic oral administration and no uricosuric effect."/>
	<sentence id="DBMI.pac171.s20" origId="s20" text="Hydrochlorothiazide\n\nAfter oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours."/>
	<sentence id="DBMI.pac171.s21" origId="s21" text="12.3 Pharmacokinetics\n\nIrbesartan\n\nIrbesartan is an orally active agent that does not require biotransformation into an active form."/>
	<sentence id="DBMI.pac171.s22" origId="s22" text="The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%."/>
	<sentence id="DBMI.pac171.s23" origId="s23" text="Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing."/>
	<sentence id="DBMI.pac171.s24" origId="s24" text="Food does not affect the bioavailability of irbesartan."/>
	<sentence id="DBMI.pac171.s25" origId="s25" text="Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range."/>
	<sentence id="DBMI.pac171.s26" origId="s26" text="The terminal elimination half-life of irbesartan averaged 11 to 15 hours."/>
	<sentence id="DBMI.pac171.s27" origId="s27" text="Steady-state concentrations are achieved within 3 days."/>
	<sentence id="DBMI.pac171.s28" origId="s28" text="Limited accumulation of irbesartan (&lt;20%) is observed in plasma upon repeated once-daily dosing."/>
	<sentence id="DBMI.pac171.s29" origId="s29" text="Hydrochlorothiazide\n\nWhen plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours."/>
	<sentence id="DBMI.pac171.s30" origId="s30" text="Metabolism and Elimination\n\nIrbesartan\n\nIrbesartan is metabolized via glucuronide conjugation and oxidation."/>
	<sentence id="DBMI.pac171.s31" origId="s31" text="Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan."/>
	<sentence id="DBMI.pac171.s32" origId="s32" text="The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%)."/>
	<sentence id="DBMI.pac171.s33" origId="s33" text="The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity."/>
	<sentence id="DBMI.pac171.s34" origId="s34" text="Irbesartan and its metabolites are excreted by both biliary and renal routes."/>
	<sentence id="DBMI.pac171.s35" origId="s35" text="Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide."/>
	<sentence id="DBMI.pac171.s36" origId="s36" text="In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible."/>
	<sentence id="DBMI.pac171.s37" origId="s37" text="Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1)."/>
	<sentence id="DBMI.pac171.s38" origId="s38" text="There was no induction or inhibition of 3A4."/>
	<sentence id="DBMI.pac171.s39" origId="s39" text="Hydrochlorothiazide\n\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney."/>
	<sentence id="DBMI.pac171.s40" origId="s40" text="At least 61% of the oral dose is eliminated unchanged within 24 hours."/>
	<sentence id="DBMI.pac171.s41" origId="s41" text="Distribution\n\nIrbesartan\n\nIrbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood."/>
	<sentence id="DBMI.pac171.s42" origId="s42" text="The average volume of distribution is 53 to 93 liters."/>
	<sentence id="DBMI.pac171.s43" origId="s43" text="Total plasma and renal clearances are in the range of 157 to 176 mL/min and 3.0 to 3.5 mL/min, respectively."/>
	<sentence id="DBMI.pac171.s44" origId="s44" text="With repetitive dosing, irbesartan accumulates to no clinically relevant extent."/>
	<sentence id="DBMI.pac171.s45" origId="s45" text="Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta."/>
	<sentence id="DBMI.pac171.s46" origId="s46" text="Irbesartan is excreted in the milk of lactating rats."/>
	<sentence id="DBMI.pac171.s47" origId="s47" text="Hydrochlorothiazide\n\nHydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk."/>
	<sentence id="DBMI.pac171.s48" origId="s48" text="Pediatric\n\nIrbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients &lt;18 years of age."/>
	<sentence id="DBMI.pac171.s49" origId="s49" text="Gender\n\nNo gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects."/>
	<sentence id="DBMI.pac171.s50" origId="s50" text="In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%)."/>
	<sentence id="DBMI.pac171.s51" origId="s51" text="No gender-related dosage adjustment is necessary."/>
	<sentence id="DBMI.pac171.s52" origId="s52" text="Geriatric\n\nIn elderly subjects (age 65 to 80 years), irbesartan elimination half-life was not significantly altered, but AUC and Cmax values were about 20% to 50% greater than those of young subjects (age 18 to 40 years)."/>
	<sentence id="DBMI.pac171.s53" origId="s53" text="No dosage adjustment is necessary in the elderly."/>
	<sentence id="DBMI.pac171.s54" origId="s54" text="Race\n\nIn healthy black subjects, irbesartan AUC values were approximately 25% greater than whites; there were no differences in Cmax values."/>
	<sentence id="DBMI.pac171.s55" origId="s55" text="Renal Insufficiency\n\nThe pharmacokinetics of irbesartan were not altered in patients with renal impairment or in patients on hemodialysis."/>
	<sentence id="DBMI.pac171.s56" origId="s56" text="Irbesartan is not removed by hemodialysis."/>
	<sentence id="DBMI.pac171.s57" origId="s57" text="No dosage adjustment is necessary in patients with mild to severe renal impairment unless a patient with renal impairment is also volume depleted."/>
	<sentence id="DBMI.pac171.s58" origId="s58" text="[See Warnings and Precautions (5.2).]"/>
	<sentence id="DBMI.pac171.s59" origId="s59" text="Hepatic Insufficiency\n\nThe pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver."/>
	<sentence id="DBMI.pac171.s60" origId="s60" text="No dosage adjustment is necessary in patients with hepatic insufficiency."/>
	<sentence id="DBMI.pac171.s61" origId="s61" text="Drug-Drug Interactions\n\nNo significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine."/>
	<sentence id="DBMI.pac171.s62" origId="s62" text="In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine."/>
	<sentence id="DBMI.pac171.s63" origId="s63" text="However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible."/>
	<sentence id="DBMI.pac171.s64" origId="s64" text="Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.">
		<entity charOffset="8604-8615" id="DBMI.pac171.s64.e0" origId="s64.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="8655-8666" id="DBMI.pac171.s64.e1" origId="s64.e1" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="8618-8638" id="DBMI.pac171.s64.e2" origId="s64.e2" text="hydrochlorothiazide " type="Active ingredient"/>
		<pair e1="DBMI.pac171.s64.e0" e2="DBMI.pac171.s64.e1" id="DBMI.pac171.s64.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac171.s64.e0" e2="DBMI.pac171.s64.e2" id="DBMI.pac171.s64.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s64.e1" e2="DBMI.pac171.s64.e0" id="DBMI.pac171.s64.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s64.e1" e2="DBMI.pac171.s64.e2" id="DBMI.pac171.s64.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s64.e2" e2="DBMI.pac171.s64.e0" id="DBMI.pac171.s64.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s64.e2" e2="DBMI.pac171.s64.e1" id="DBMI.pac171.s64.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="hydrochlorothiazide "/>
	</sentence>
	<sentence id="DBMI.pac171.s65" origId="s65" text="Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4."/>
	<sentence id="DBMI.pac171.s66" origId="s66" text="In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.">
		<entity charOffset="8959-8970" id="DBMI.pac171.s66.e0" origId="s66.e0" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="8916-8925" id="DBMI.pac171.s66.e1" origId="s66.e1" text="warfarin " type="Active ingredient"/>
		<entity charOffset="8950-8958" id="DBMI.pac171.s66.e2" origId="s66.e2" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac171.s66.e0" e2="DBMI.pac171.s66.e1" id="DBMI.pac171.s66.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="irbesartan "/>
		<pair e1="DBMI.pac171.s66.e0" e2="DBMI.pac171.s66.e2" id="DBMI.pac171.s66.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="irbesartan "/>
		<pair e1="DBMI.pac171.s66.e1" e2="DBMI.pac171.s66.e0" id="DBMI.pac171.s66.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s66.e1" e2="DBMI.pac171.s66.e2" id="DBMI.pac171.s66.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s66.e2" e2="DBMI.pac171.s66.e0" id="DBMI.pac171.s66.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s66.e2" e2="DBMI.pac171.s66.e1" id="DBMI.pac171.s66.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac171.s67" origId="s67" text="The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.">
		<entity charOffset="9177-9188" id="DBMI.pac171.s67.e0" origId="s67.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="9125-9136" id="DBMI.pac171.s67.e1" origId="s67.e1" text="irbesartan " type="Active ingredient"/>
		<pair e1="DBMI.pac171.s67.e0" e2="DBMI.pac171.s67.e1" id="DBMI.pac171.s67.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac171.s67.e1" e2="DBMI.pac171.s67.e0" id="DBMI.pac171.s67.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac171.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nIrbesartan\n\nAngiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor."/>
	<sentencespan id="DBMI.pac171.sp1" origId="sp1" text="There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity. Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure."/>
	<sentencespan id="DBMI.pac171.sp2" origId="sp2" text="Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis. Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known. Hydrochlorothiazide\n\nHydrochlorothiazide is a thiazide diuretic."/>
	<sentencespan id="DBMI.pac171.sp3" origId="sp3" text="Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics."/>
	<sentencespan id="DBMI.pac171.sp4" origId="sp4" text="The mechanism of the antihypertensive effect of thiazides is not fully understood. 12.2 Pharmacodynamics\n\nIrbesartan\n\nIn healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions. Inhibition was complete (100%) 4 hours following oral doses of 150 mg or 300 mg and partial inhibition was sustained for 24 hours (60% and 40% at 300 mg and 150 mg, respectively)."/>
	<sentencespan id="DBMI.pac171.sp5" origId="sp5" text="In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels. Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses. In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction."/>
	<sentencespan id="DBMI.pac171.sp6" origId="sp6" text="In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations. There was no effect on serum uric acid during chronic oral administration and no uricosuric effect. Hydrochlorothiazide\n\nAfter oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours."/>
	<sentencespan id="DBMI.pac171.sp7" origId="sp7" text="12.3 Pharmacokinetics\n\nIrbesartan\n\nIrbesartan is an orally active agent that does not require biotransformation into an active form. The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%. Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing."/>
	<sentencespan id="DBMI.pac171.sp8" origId="sp8" text="Food does not affect the bioavailability of irbesartan. Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range. The terminal elimination half-life of irbesartan averaged 11 to 15 hours."/>
	<sentencespan id="DBMI.pac171.sp9" origId="sp9" text="Steady-state concentrations are achieved within 3 days. Limited accumulation of irbesartan (&lt;20%) is observed in plasma upon repeated once-daily dosing. Hydrochlorothiazide\n\nWhen plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours."/>
	<sentencespan id="DBMI.pac171.sp10" origId="sp10" text="Metabolism and Elimination\n\nIrbesartan\n\nIrbesartan is metabolized via glucuronide conjugation and oxidation. Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan. The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%)."/>
	<sentencespan id="DBMI.pac171.sp11" origId="sp11" text="The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity. Irbesartan and its metabolites are excreted by both biliary and renal routes. Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide."/>
	<sentencespan id="DBMI.pac171.sp12" origId="sp12" text="In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible. Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1). There was no induction or inhibition of 3A4."/>
	<sentencespan id="DBMI.pac171.sp13" origId="sp13" text="Hydrochlorothiazide\n\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated unchanged within 24 hours. Distribution\n\nIrbesartan\n\nIrbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood."/>
	<sentencespan id="DBMI.pac171.sp14" origId="sp14" text="The average volume of distribution is 53 to 93 liters. Total plasma and renal clearances are in the range of 157 to 176 mL/min and 3.0 to 3.5 mL/min, respectively. With repetitive dosing, irbesartan accumulates to no clinically relevant extent."/>
	<sentencespan id="DBMI.pac171.sp15" origId="sp15" text="Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta. Irbesartan is excreted in the milk of lactating rats. Hydrochlorothiazide\n\nHydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk."/>
	<sentencespan id="DBMI.pac171.sp16" origId="sp16" text="Pediatric\n\nIrbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients &lt;18 years of age. Gender\n\nNo gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects. In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%)."/>
	<sentencespan id="DBMI.pac171.sp17" origId="sp17" text="No gender-related dosage adjustment is necessary. Geriatric\n\nIn elderly subjects (age 65 to 80 years), irbesartan elimination half-life was not significantly altered, but AUC and Cmax values were about 20% to 50% greater than those of young subjects (age 18 to 40 years). No dosage adjustment is necessary in the elderly."/>
	<sentencespan id="DBMI.pac171.sp18" origId="sp18" text="Race\n\nIn healthy black subjects, irbesartan AUC values were approximately 25% greater than whites; there were no differences in Cmax values. Renal Insufficiency\n\nThe pharmacokinetics of irbesartan were not altered in patients with renal impairment or in patients on hemodialysis. Irbesartan is not removed by hemodialysis."/>
	<sentencespan id="DBMI.pac171.sp19" origId="sp19" text="No dosage adjustment is necessary in patients with mild to severe renal impairment unless a patient with renal impairment is also volume depleted. [See Warnings and Precautions (5.2).] Hepatic Insufficiency\n\nThe pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver."/>
	<sentencespan id="DBMI.pac171.sp20" origId="sp20" text="No dosage adjustment is necessary in patients with hepatic insufficiency. Drug-Drug Interactions\n\nNo significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine. In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine."/>
	<sentencespan id="DBMI.pac171.sp21" origId="sp21" text="However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible. Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics. Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.">
		<entity charOffset="8604-8615" id="DBMI.pac171.sp21.e0" origId="sp21.e0" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="8655-8666" id="DBMI.pac171.sp21.e1" origId="sp21.e1" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="8618-8638" id="DBMI.pac171.sp21.e2" origId="sp21.e2" text="hydrochlorothiazide " type="Active ingredient"/>
		<pair e1="DBMI.pac171.sp21.e0" e2="DBMI.pac171.sp21.e1" id="DBMI.pac171.sp21.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac171.sp21.e0" e2="DBMI.pac171.sp21.e2" id="DBMI.pac171.sp21.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e1" e2="DBMI.pac171.sp21.e0" id="DBMI.pac171.sp21.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e1" e2="DBMI.pac171.sp21.e2" id="DBMI.pac171.sp21.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e2" e2="DBMI.pac171.sp21.e0" id="DBMI.pac171.sp21.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e2" e2="DBMI.pac171.sp21.e1" id="DBMI.pac171.sp21.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="hydrochlorothiazide "/>
	</sentencespan>
	<sentencespan id="DBMI.pac171.sp22" origId="sp22" text="In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin. The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.">
		<entity charOffset="8959-8970" id="DBMI.pac171.sp22.e0" origId="sp22.e0" text="irbesartan " type="Active ingredient"/>
		<entity charOffset="8916-8925" id="DBMI.pac171.sp22.e1" origId="sp22.e1" text="warfarin " type="Active ingredient"/>
		<entity charOffset="8950-8958" id="DBMI.pac171.sp22.e2" origId="sp22.e2" text="digoxin " type="Active ingredient"/>
		<entity charOffset="9177-9188" id="DBMI.pac171.sp22.e3" origId="sp22.e3" text="nifedipine " type="Active ingredient"/>
		<entity charOffset="9191-9211" id="DBMI.pac171.sp22.e4" origId="sp22.e4" text="hydrochlorothiazide " type="Active ingredient"/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin " precipitant="irbesartan "/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin " precipitant="irbesartan "/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="nifedipine "/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan " precipitant="hydrochlorothiazide "/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>
